down arrow

Oragenics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6840235005
USD
0.85
-0.01 (-1.49%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.850.89

52 Week

0.8218.90
Valuation
Technical
Day's Volume

CASH

52.62 k

Shareholding (Mar 2025)

FII

0.20%

Held by 4 FIIs

DII

99.09%

Held by 1 DIIs

Promoter

0.00%

How big is Oragenics, Inc.?

22-Jun-2025

As of Jun 18, Oragenics, Inc. has a market capitalization of 3.13 million, with net sales of 0.00 million and a net profit of -10.34 million over the latest four quarters. The company reported shareholder's funds of -0.21 million and total assets of 1.47 million as of Dec 24.

Market Cap: As of Jun 18, Oragenics, Inc. has a market capitalization of 3.13 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Oragenics, Inc. reported net sales of 0.00 million and a net profit of -10.34 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -0.21 million and total assets of 1.47 million.

Read More

What does Oragenics, Inc. do?

22-Jun-2025

Oragenics, Inc. is a micro-cap healthcare company focused on developing treatments for oral mucositis and novel antibiotics. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $3.13 million.

Overview:<BR>Oragenics, Inc. is a healthcare company focused on developing treatments for oral mucositis and novel antibiotics against infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 3.13 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.87<BR>Return on Equity: -1,033.41%<BR>Price to Book: 3.13<BR><BR>Contact Details:<BR>Address: 4902 Eisenhower Blvd Ste 125, TAMPA FL: 33634-6342<BR>Tel: 1 813 2867900<BR>Fax: 1 813 2867904<BR>Website: https://www.oragenics.com/

Read More

Who are in the management team of Oragenics, Inc.?

22-Jun-2025

As of March 2022, the management team of Oragenics, Inc. includes Dr. Frederick Telling (Independent Chairman), Dr. Alan Joslyn (President and CEO), Ms. Kim Murphy, Dr. Alan Dunton, Mr. Robert Koski, and Mr. Charles Pope, all serving as directors. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Oragenics, Inc. includes the following individuals:<BR><BR>- Dr. Frederick Telling, who serves as the Independent Chairman of the Board.<BR>- Dr. Alan Joslyn, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Kim Murphy, who is a Director.<BR>- Dr. Alan Dunton, who is an Independent Director.<BR>- Mr. Robert Koski, who is also an Independent Director.<BR>- Mr. Charles Pope, who serves as an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Oragenics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 12, 2016, Oragenics, Inc. is considered overvalued due to its negative financial metrics, including a non-applicable P/E ratio, a Price to Book Value of 3.06, an EV to EBITDA of -0.22, and a severely low ROE of -1033.41%, alongside significant underperformance compared to the S&P 500.

As of 12 August 2016, the valuation grade for Oragenics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 3.06, and an EV to EBITDA of -0.22. The return on equity (ROE) is alarmingly low at -1033.41%, reflecting severe operational challenges.<BR><BR>In comparison to its peers, Oragenics, Inc. shows a less favorable position; for instance, Lexaria Bioscience Corp. has a P/E of -2.0847 and an EV to EBITDA of -1.4100, while Cyclerion Therapeutics, Inc. has a P/E of -3.0156 and an EV to EBITDA of -1.8268, both indicating similar struggles within the industry. The company's stock has underperformed significantly against the S&P 500, with a year-to-date decline of 67.87% compared to the index's modest gain of 2.44%. Overall, the combination of these factors strongly suggests that Oragenics, Inc. is overvalued.

Read More

Is Oragenics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Oragenics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with year-to-date returns of -89.08% compared to 12.22%.

As of 8 September 2025, the technical trend for Oragenics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates bullish momentum weekly and monthly. However, moving averages are bearish on a daily basis, and the KST and Bollinger Bands are bearish on both weekly and monthly time frames. Dow Theory shows a mildly bullish stance weekly but bearish monthly, and OBV is mildly bullish weekly but bearish monthly.<BR><BR>In terms of performance, Oragenics has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.08% versus the S&P 500's 12.22%, and a one-year return of -91.65% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.48

stock-summary
Return on Equity

484.14%

stock-summary
Price to Book

-2.27

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.66%
0%
-19.66%
6 Months
-76.98%
0%
-76.98%
1 Year
-91.13%
0%
-91.13%
2 Years
-99.22%
0%
-99.22%
3 Years
-99.76%
0%
-99.76%
4 Years
-99.9%
0%
-99.9%
5 Years
-99.9%
0%
-99.9%

Oragenics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Oragenics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Oragenics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates bullish momentum weekly and monthly. However, moving averages are bearish on a daily basis, and the KST and Bollinger Bands are bearish on both weekly and monthly time frames. Dow Theory shows a mildly bullish stance weekly but bearish monthly, and OBV is mildly bullish weekly but bearish monthly. In terms of performance, Oragenics has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.08% versus the S&P 500's 12.22%, and a one-year return of -91.65% compared to 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
10.15%
EBIT to Interest (avg)
-15.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.99%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.06
EV to EBIT
-0.22
EV to EBITDA
-0.22
EV to Capital Employed
-2.20
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1033.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.71%)

Foreign Institutions

Held by 4 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -4.55% vs 33.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-2.00",
          "chgp": "15.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.20",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-2.20",
          "chgp": "-4.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 48.79% vs -44.76% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.60",
          "val2": "-10.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-10.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-20.70",
          "chgp": "48.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.70
-2.00
15.00%
Interest
0.60
0.20
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.30
-2.20
-4.55%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -4.55% vs 33.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.60
-10.60
Interest
0.00
0.00
Exceptional Items
0.00
-10.30
100.00%
Consolidate Net Profit
-10.60
-20.70
48.79%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 48.79% vs -44.76% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Oragenics, Inc. stock-summary
stock-summary
Oragenics, Inc.
Pharmaceuticals & Biotechnology
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.
Company Coordinates stock-summary
Company Details
4902 Eisenhower Blvd Ste 125 , TAMPA FL : 33634-6342
stock-summary
Tel: 1 813 2867900
stock-summary
https://www.oragenics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."